The Requirement for Cyclin D Function in Tumor Maintenance

Cited by (342)

Items 101–200 of 342

1. Zyxin promotes colon cancer tumorigenesis in a mitotic phosphorylation-dependent manner and through CDK8-mediated YAP activation
   Jiuli Zhou, Yongji Zeng, Lian Cui, Xingcheng Chen, Seth Stauffer, Zhan Wang, Fang Yu, Subodh M. Lele, Geoffrey A. Talmon, Adrian R. Black et al. · 2018 · Proceedings of the National Academy of Sciences
2. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
   Ami N. Shah, Massimo Cristofanilli · 2017 · Current Treatment Options in Oncology
3. Progress with palbociclib in breast cancer: latest evidence and clinical considerations
   Andrea Rocca, Alessio Schirone, Roberta Maltoni, Sara Bravaccini, Lorenzo Cecconetto, Alberto Farolfi, Giuseppe Bronte, Daniele Andreis · 2016 · Therapeutic Advances in Medical Oncology
4. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth
   Congren Wang, XUEJIN WANG, Zijian Su, Hong-jiang Fei, Xiaoyu Liu, Qunxiong Pan · 2015 · Oncology Reports
5. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma
   Anthony M. Robinson, Richa Rathore, Nathan J. Redlich, Douglas R. Adkins, Todd L. VanArsdale, Brian Andrew Van Tine, Loren Scott Michel · 2019 · Cell Death and Disease
6. D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells
   Qian Zhang, Kazuhito Sakamoto, Kay‐Uwe Wagner · 2013 · Molecular and Cellular Endocrinology
7. Impact of somatic and germline mutations on the outcome of systemic mastocytosis
   Javier I. Muñoz‐González, María Jara‐Acevedo, Iván Álvarez‐Twöse, Jason D. Merker, Cristina Teodósio, Yanli Hou, Ana Henriques, Krishna M. Roskin, Laura Sánchez‐Muñoz, Albert G. Tsai et al. · 2018 · Blood Advances
8. A negative reciprocal regulatory axis between cyclin D1 and HNF4α modulates cell cycle progression and metabolism in the liver
   Heng Wu, Yitzhak Reizel, Yue Julia Wang, Jessica L. Lapiro, Betsy T. Kren, Jonathan Schug, Shilpa J. Rao, Ashleigh R. Morgan, Adam Herman, Laurie L. Shekels et al. · 2020 · Proceedings of the National Academy of Sciences
9. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance
   Yuesheng Zhang · 2020 · Pharmacology & Therapeutics
10. Advances of small molecule targeting of kinases
    Norbert Berndt, Rezaul M. Karim, E. Schönbrunn · 2017 · Current Opinion in Chemical Biology
11. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms
    Margaretha A. Skowron, Marieke Vermeulen, Anna Winkelhausen, Teresa K. Becker, Felix Bremmer, Patrick Petzsch, Stefan Schönberger, Gabriele Calaminus, Karl Köhrer, Peter Albers et al. · 2020 · British Journal of Cancer
12. New Approaches to Target T-ALL
    Giovanni Roti, Kimberly Stegmaier · 2014 · Frontiers in Oncology
13. Kinase-independent function of E-type cyclins in liver cancer
    Yan Geng, Wojciech Michowski, Joel M. Chick, Yaoyu E. Wang, Marie Jecrois, Katharine E. Sweeney, Lijun Liu, Richard C. Han, Nan Ke, Agnieszka Zagożdżon et al. · 2018 · Proceedings of the National Academy of Sciences
14. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
    Mary E. Klein, Mark Andrew Dickson, Cristina R. Antonescu, Li‐Xuan Qin, Scott J. Dooley, Afşar Barlas, Katia Manova, Gary K. Schwartz, Aimee Marie Crago, Samuel Singer et al. · 2018 · Oncogene
15. Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia
    Xueliang Gao, Shenghui Qin, Yongxia Wu, Chen Chu, Baishan Jiang, Roger H. Johnson, Dong Kuang, Jie Zhang, Xi Wang, Anand S. Mehta et al. · 2021 · Journal of Clinical Investigation
16. Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles
    Yihong He, Xin Zan, Junming Miao, Bilan Wang, Yuankai Wu, Yangmei Shen, Xinchuan Chen, Hongfeng Gou, Songping Zheng, Ning Huang et al. · 2022 · Materials Today Bio
17. The other side of the coin: The tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND–CDK4/6–RB axis
    Xiaomin Lou, Ju Zhang, Siqi Liu, Xiaomin Lou, Dezhong Joshua Liao · 2014 · Cell Cycle
18. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Adriana Reis Brandão Matutino, Carla Pires Amaro, Sunil Verma · 2018 · Therapeutic Advances in Medical Oncology
19. Combination of PARP inhibitor and CDK4 /6 inhibitor modulates cGAS / STING‐ dependent therapy‐induced senescence and provides “one‐two punch” opportunity with anti‐PD‐L1 therapy in colorectal cancer
    Tao Wang, Weizhen Liu, Qian Shen, Ruikang Tao, Chengguo Li, Qian Shen, Yao Lin, Yongzhou Huang, Lei Yang, Gengchen Xie et al. · 2023 · Cancer Science
20. Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
    Otto Metzger, Sumithra J. Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier González, Prudence A. Francis et al. · 2026 · New England Journal of Medicine
21. A miR‐194/PTBP1/CCND3 axis regulates tumor growth in human hepatocellular carcinoma
    Hoin Kang, Sungeun Heo, Jung Jae Shin, Eunbyul Ji, Hyosun Tak, Sojin Ahn, Kyung Jin Lee, Eun Kyung Lee, Wook Kim · 2019 · The Journal of Pathology
22. SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
    Akihiro Yoshida, Yiwen Bu, Shuo Qie, John M. Wrangle, Ernest Ramsay Camp, E. Starr Hazard, Gary Hardiman, Renée de Leeuw, Karen E. Knudsen, John Alan Diehl · 2019 · Science Advances
23. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
    Adina Gerson‐Gurwitz, Nathan P. Young, Vikas Goel, Boreth Eam, Craig R. Stumpf, Joan W. Chen, Sarah Fish, Maria Barrera, Eric Sung, Jocelyn Staunton et al. · 2021 · Frontiers in Oncology
24. Cyclin‐dependent kinases: Masters of the eukaryotic universe
    Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, Chris J. Norbury · 2023 · Wiley Interdisciplinary Reviews - RNA
25. NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation
    Amit Bera, Nandini Ghosh‐Choudhury, Nirmalya Dey, Falguni Das, Balakuntalam S. Kasinath, Hanna E. Abboud, Goutam Ghosh Choudhury · 2013 · Cellular Signalling
26. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors
    Pietro Sollena, Vasiliki A. Nikolaou, Nikolaos Soupos, Elias Alexandros Kotteas, Dimitra Voudouri, Alexandros Stratigos, Davide Fattore, Maria Carmela Annunziata, Armando Orlandi, Lucia Di Nardo et al. · 2020 · Breast Cancer Research and Treatment
27. Pan-Cancer Analysis Reveals Synergistic Effects of CDK4/6i and PARPi Combination Treatment in RB-Proficient and RB-Deficient Breast Cancer Cells
    Songyu Li, Yixiang Zhang, Na Wang, Rong Guo, Qiaoling Liu, Changsheng Lv, Jinguang Wang, Lina Wang, Qingkai Yang · 2018 · Cell Death and Disease
28. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
    Vishnu Muthuraj Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna R. Rosenheck, Sivasankar Putta, Alec G. Trub, John Bisi, Jay C. Strum et al. · 2025 · Nature Communications
29. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer
    Burak Bi̇lgi̇n, Mehmet Alı Nahıt Şendur, Didem Şener Dede, Muhammed Bülent Akıncı, Bülent Yalçın · 2017 · Current Medical Research and Opinion
30. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment
    Jing Li, Jun Jiang, Jianmei Wu, Xun Bao, Nader Sanai · 2020 · Clinical Pharmacology & Therapeutics
31. CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia
    Nilamani Jena, Jinghao Sheng, Jamie Katy Hu, W Li, Wenhui Zhou, Gabriel Lee, N Tsichlis, Apana Pathak, Nelson E. Brown, Amit Deshpande et al. · 2015 · Leukemia
32. Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia
    Tze King Tan, Chujing Zhang, Takaomi Sanda · 2018 · International Journal of Hematology
33. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
    Kai Zhang, Ruoxi Hong, Kaping Lee, Fei Xu, Wen Xia, Ge Qin, Qiufan Zheng, Qianyi Lu, Qinglian Zhai, Yanxia Shi et al. · 2019 · Cancer Letters
34. Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition
    Jing Gao, Hanwu Zhang, Fengqi Zhou, Bo Hou, Meiwan Chen, Zhigang Xie, Haijun Yu · 2020 · Chinese Chemical Letters
35. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
    Sabine Paternot, Colleoni Bianca, Xavier Bisteau, Pierre P. Roger · 2014 · Cell Cycle
36. Selective Pro-Apoptotic Activity of Novel 3,3′-(Aryl/Alkyl-Methylene)Bis(2-Hydroxynaphthalene-1,4-Dione) Derivatives on Human Cancer Cells via the Induction Reactive Oxygen Species
    Pritam Sadhukhan, Sukanya Saha, Krishnendu Sinha, Goutam Brahmachari, Parames Chandra Sil · 2016 · PLoS ONE
37. Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells
    Parham Ramezani-Rad, Cindi Chen, Zilu Zhu, Robert C. Rickert · 2020 · Cell Reports
38. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
    Valerio Nardone, Marcella Barbarino, Antonio Angrisani, Pierpaolo Correale, Pierpaolo Pastina, Salvatore Cappabianca, Alfonso Reginelli, Luciano Mutti, Clelia Miracco, Rocco Giannicola et al. · 2021 · International Journal of Molecular Sciences
39. Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options
    Giulia Grizzi, Michele Ghidini, Andrea Botticelli, Gianluca Tomasello, Antonio Ghidini, Francesco Grossi, Nicola Fusco, Mary Cabiddu, Tommaso Savio, Fausto Petrelli · 2020 · Cancer Management and Research
40. Mechanisms of Resistance to Checkpoint Blockade Therapy
    Hubing Shi, Jiang Lan, Jiqiao Yang · 2020 · Advances in experimental medicine and biology
41. Changes in the mammary gland during aging and its links with breast diseases
    Junqiang Lin, Shihui Ye, Ke Hao, Liang Lin, Xia Wu, Mengfei Guo, Baowei Jiao, Ceshi Chen, Limin Zhao · 2023 · Acta Biochimica et Biophysica Sinica
42. Feedback, Crosstalk and Competition: Ingredients for Emergent Non-Linear Behaviour in the PI3K/mTOR Signalling Network
    Milad Ghomlaghi, Anthony Hart, Nhan Hoang, Sung‐Young Shin, Lan K. Nguyen · 2021 · International Journal of Molecular Sciences
43. Individualizing breast cancer treatment—The dawn of personalized medicine
    Argha Nandy, Sudeshna Gangopadhyay, Ashis Mukhopadhyay · 2013 · Experimental Cell Research
44. Cyclin d1 depletion interferes with cancer oxidative balance and sensitizes cancer cells to senescence
    Phatthamon Laphanuwat, Pornlada Likasitwatanakul, Gunya Sittithumcharee, Araya Thaphaengphan, Nussara Chomanee, Orawan Suppramote, Nuttavadee Ketaroonrut, Komgrid Charngkaew, Eric W.‐F. Lam, Seiji Okada et al. · 2018 · Journal of Cell Science
45. Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
    Alessandra Dall’Acqua, Michele Bartoletti, Nastaran Masoudi-Khoram, Roberto Sorio, Fabio Puglisi, Barbara Belletti, Gustavo Baldassarre · 2021 · Cancers
46. Hyper-dependence of breast cancer cell types on the nuclear transporter Importin β1
    Henna V. Kuusisto, David A. Jans · 2015 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
47. JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
    B Colleoni, Sabine Paternot, Jaime Miguel Gomes Pita, Xavier Bisteau, Katia Coulonval, Roger J. Davis, Eric Raspé, Pierre P. Roger · 2017 · Oncogene
48. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT
    Azadeh Elmi, Mehran Makvandi, Chi-Chang Weng, Catherine Hou, Amy Sanders Clark, Robert H. Mach, David A. Mankoff · 2019 · Clinical Cancer Research
49. S100A12 is a promising biomarker in papillary thyroid cancer
    Xiaojie Wang, Zhenxiang Sun, Wei Tian, Chenghao Piao, Xiaochen Xie, Jin Zang, Shiqiao Peng, Xiaohui Yu, Yiwei Wang · 2020 · Scientific Reports
50. Notch in Leukemia
    Anna C. McCarter, Qing Wang, Mark Y. Chiang · 2018 · Advances in experimental medicine and biology
51. Clinical significance of microRNA 138 and cyclin D3 in hepatocellular carcinoma
    Bo Huang, Huiwen Li, Liyu Huang, Chaoyuan Luo, Ying Zhang · 2014 · Journal of Surgical Research
52. β-Caryophyllene promotes oxidative stress and apoptosis in KB cells through activation of mitochondrial-mediated pathway – An in-vitro and in-silico study
    Duraisamy Ramachandhiran, Chandrasekaran Sankaranarayanan, Raju Murali, Sukumar Babukumar, Veerasamy Vinothkumar · 2019 · Archives of Physiology and Biochemistry
53. How selective are clinical CDK4/6 inhibitors?
    Denisa Hendrychová, Radek Jorda, Vladimı́r Kryštof · 2020 · Medicinal Research Reviews
54. DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1
    Juan Huertas-Martínez, Franck Court, Santiago Rello‐Varona, David Herrero‐Martín, Olga Almacellas‐Rabaiget, Miguel Sáinz‐Jaspeado, Sílvia García-Monclús, Laura Lagares‐Tena, Raquel Buj, Lourdes Hontecillas‐Prieto et al. · 2016 · Cancer Letters
55. Cyclin-dependent kinase inhibitors for the treatment of lung cancer
    Angel Qin, Haritha G. Reddy, Frank D. Weinberg, Gregory Peter Kalemkerian · 2020 · Expert Opinion on Pharmacotherapy
56. Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia
    Rachael Pocock, Nadine Farah, Simon E. Richardson, Marc R. Mansour · 2021 · British Journal of Haematology
57. From cyclins to CDKIs: Cell cycle regulation of skeletal muscle stem cell quiescence and activation
    Despoina Mademtzoglou, Frédéric Relaix · 2022 · Experimental Cell Research
58. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting
    Ashna Gupta, Gunjan Dagar, Ravi Chauhan, Hana Q. Sadida, Sara K. Al-Marzooqi, Sheema Hashem, Shahab Uddin M.S., Muzafar Ahmad Macha, Ammira S. Al-Shabeeb Akil, Tej Krishan Pandita et al. · 2023 · Advances in protein chemistry and structural biology
59. Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia
    Hidemasa Matsuo, Kenichi Yoshida, Kazutaka Fukumura, Kana Nakatani, Yuki Noguchi, Saho Takasaki, Mina Noura, Yusuke Shiozawa, Yuichi Shiraishi, Kenichi Chiba et al. · 2018 · Blood Advances
60. Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi
    Manuel Kaulich, Yeon J. Lee, Peter Lönn, Aaron D. Springer, Bryan R. Meade, Steven F. Dowdy · 2015 · Nucleic Acids Research
61. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin‐dependent kinases 4 and 6 as anticancer agents
    Solomon Tadesse, Laychiluh Bantie Mekonnen, Khamis Tomusange, Mingfeng Yu, Saiful Islam, Nataliya Bykovska, Benjamin D. Noll, Ge Zhu, Peng Li, Frankie Lam et al. · 2017 · British Journal of Pharmacology
62. D-Cyclins Repress Apoptosis in Hematopoietic Cells by Controlling Death Receptor Fas and Its Ligand FasL
    Yoon Jong Choi, Borja Sáez, Lars Anders, Per Hydbring, Joanna Stefano, Nickolas A. Bacon, Colleen Cook, Ilona Kalaszczyńska, Sabina Signoretti, Richard A. Young et al. · 2014 · Developmental Cell
63. Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells
    Weijie Cao, KE WU, Chong Wang, Dingming Wan · 2016 · Molecular Medicine Reports
64. Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST
    Inga‐Marie Schaefer, Matthew L. Hemming, Meijun Z. Lundberg, Matthew P. Serrata, Isabel Goldaracena, Ninning Liu, Peng Yin, João A. Paulo, Steven P. Gygi, Suzanne George et al. · 2022 · British Journal of Cancer
65. The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis
    Siwanon Jirawatnotai, Samanta Sharma, Wojciech Michowski, Bhoom Suktitipat, Yan Geng, John F Quackenbush, Joshua Eric Elias, Steven P. Gygi, Yaoyu E. Wang, Piotr Siciński · 2014 · Cell Cycle
66. Mass spectrometry–based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells
    Ian M. McDonald, Gavin D. Grant, Michael P. East, Thomas S.K. Gilbert, Emily Wilkerson, Dennis Goldfarb, Joshua Beri, Laura E. Herring, Cyrus Vaziri, Jeanette Gowen Cook et al. · 2020 · Journal of Biological Chemistry
67. Preventive Efficacy of Vanillic Acid on Regulation of Redox Homeostasis, Matrix Metalloproteinases and Cyclin D1 in Rats Bearing Endometrial Carcinoma
    Pakkiri Bhavani, P. Subramanian, Sivamani Kanimozhi · 2016 · Indian Journal of Clinical Biochemistry
68. Operculina turpethum extract inhibits growth and proliferation by inhibiting NF-κB, COX-2 and cyclin D1 and induces apoptosis by up regulating P53 in oral cancer cells
    Ritu Arora, Vijaya Bharti, Poonam Gaur, Sadhna Aggarwal, Manasi Mittal, Satya Narayan Das · 2017 · Archives of Oral Biology
69. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling
    Jing Yi Tang, Yan Liao, Shuying He, Jie Shi, Liang Peng, Xiaoping Xu, Fang Xie, Na Diao, Jinlan Huang, Qian Reuben Xie et al. · 2017 · Journal of Translational Medicine
70. Novel treatment strategies for patients with HER2‑positive breast cancer who do not benefit from current targeted therapy drugs (Review)
    Nan Jiang, Jingjing Lin, Jun Wang, Bei‐Ning Zhang, Ao Li, Zheng‐Yang Chen, Song Guo, Binbin Li, Yu‐zhong Duan, Ru‑Yi Yan et al. · 2018 · Experimental and Therapeutic Medicine
71. Expression of cyclin-dependent kinases and their clinical significance with immune infiltrates could predict prognosis in colorectal cancer
    Adewale Oluwaseun Fadaka, Nicole Remaliah Samantha Sibuyi, Olalekan Olanrewaju Bakare, Ashwil Klein, Abram Madimabe Madiehe, Mervin Meyer · 2021 · Biotechnology Reports
72. On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
    Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul‐Gi Kim, Gun Min Kim, Tae Yeong Kim, Won‐Ji Ryu, Jee Ye Kim, Hyung Seok Park, Seho Park et al. · 2023 · Breast Cancer Research
73. CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis
    Naema Nayyar, Magali A. de Sauvage, Jane Chuprin, Emily M. Sullivan, Mohini Singh, Consuelo Torrini, Britney S. Zhang, Sushobhana Bandyopadhyay, Keith A. Daniels, Christopher A Alvarez-Breckenridge et al. · 2023 · Clinical Cancer Research
74. Ellagic Acid Normalizes Mitochondrial Outer Membrane Permeabilization and Attenuates Inflammation-Mediated Cell Proliferation in Experimental Liver Cancer
    Srisesharam Srigopalram, Indira A. Jayraaj, B. Kaleeswaran, K. Balamurugan, M. Ranjithkumar, T. Senthil Kumar, Jong‐In Park, Ill–Sup Nou · 2014 · Applied Biochemistry and Biotechnology
75. Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas and Paired Normal Mucosae Reveals Cyclin D1 Deregulation and Compensatory Effect of Cyclin D2
    Jiří Novotný, Veronika Bandúrová, Hynek Strnad, Martin Chovanec, Miluše Hradilová, Jana Šáchová, Martin Šteffl, Josipa Grušanović, Roman Kodet, Václav Pačes et al. · 2020 · Cancers
76. The Kinase-Independent, Second Life of CDK6 in Transcription
    Tobias Otto, Piotr Siciński · 2013 · Cancer Cell
77. Tomentosin induces apoptotic pathway by blocking inflammatory mediators via modulation of cell proteins in AGS gastric cancer cell line
    Hongwei Yang, Hongchao Zhao, Xinhua Dong, Zhen Yang, Weilong Chang · 2020 · Journal of Biochemical and Molecular Toxicology
78. Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD)
    Jieru Zhang, Hui Xu, Xiaomei Yang, Yuanjie Zhao, Xinchun Xu, Ling Zhang, Xiaofeng Xuan, Chunping Ma, Wenxia Qian, Dawei Li · 2020 · Journal of Cancer
79. Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
    Yuanhang Yu, Han Liao, Rong Xie, Yue Zhang, Renjing Zheng, Jianying Chen, Bo Zhang · 2020 · Frontiers in Oncology
80. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
    Raajit K. Rampal, Maria C. Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara, Benjamin Heath Durham, Richard P. Koche, Barbara G. Spitzer, Shoron Mowla, Aishwarya Krishnan, Bing Li, Wenbin An et al. · 2021 · Clinical Cancer Research
81. Extraction Optimization, Structural Characterization, and Anti-Hepatoma Activity of Acidic Polysaccharides From Scutellaria barbata D. Don
    Wenwen Su, Leilei Wu, Qichao Liang, Xiaoyue Lin, Xiaoyi Xu, Shikai Yu, Yitong Lin, Jiadong Zhou, Fu Yang, Xiaoyan Gao et al. · 2022 · Frontiers in Pharmacology
82. Cell Cycle-Based Therapies Move Forward
    Marcos Malumbres · 2012 · Cancer Cell
83. Toward innovative combinational immunotherapy: A systems biology perspective
    Xuetao Li, Jin‐Ji Yang, Yi-Long Lung Cancer Wu, Jun Hou · 2018 · Cancer Treatment Reviews
84. Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches
    Anna Richter, Nina Schoenwaelder, Sina Sender, Christian Junghanss, Claudia Maletzki · 2021 · Cancers
85. Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth
    Shamshad Alam, Amanda Zunic, Swati Venkat, Michael E. Feigin, Boyko S. Atanassov · 2022 · Molecular Cancer Research
86. Effects of SOST Gene Silencing on Proliferation, Apoptosis, Invasion, and Migration of Human Osteosarcoma Cells Through the Wnt/β-Catenin Signaling Pathway
    Jian Zou, Wei Zhang, Xiaolin Li · 2017 · Calcified Tissue International
87. TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity
    Gang Yan, Meiou Dai, Chenjing Zhang, Sophie Poulet, Alaa Moamer, Ni Wang, Julien Boudreault, Suhad Ali, J J Lebrun · 2021 · Oncogenesis
88. The molecular mechanism of neutrophil extracellular traps and its role in bone and joint disease
    Mengting Xiang, Meng Yin, Siwen Xie, Liang Shi, Wei Nie, Bin Shi, Gongchang Yu · 2023 · Heliyon
89. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
    Inês Gomes, Catarina Abreu, Luís Costa, Sandra Casimiro · 2023 · Cancers
90. Ubiquitin specific protease 2 acts as a key modulator for the regulation of cell cycle by adiponectin and leptin in cancer cells
    Saroj Nepal, Anup Shrestha, Pil‐Hoon Park · 2015 · Molecular and Cellular Endocrinology
91. Retracted: Ganoderma lucidum Exerts an Anticancer Effect on Human Osteosarcoma Cells via Suppressing the Wnt/β-Catenin Signaling Pathway
    Qihao Zhang, Qin-Xiao Hu, Da Xie, Bo Chang, Houguang Miao, Yunguo Wang, Dezhong Liu, Xuedong Li · 2019 · Integrative Cancer Therapies · Retracted
92. CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia
    Franz Ketzer, Hend Abdelrasoul, Mona Vogel, Ralf B. Marienfeld, Markus Müschen, Hassan Jumaa, Thomas Wirth, Alexey Ushmorov · 2022 · Oncogenesis
93. PALVEN: Phase Ib Trial of Palbociclib, Letrozole and Venetoclax in Estrogen Receptor- and BCL2-Positive Advanced Breast Cancer
    Christine Muttiah, James Richard Whittle, Catherine Angela Oakman, Geoffrey John Lindeman · 2022 · Future Oncology
94. Misexpression of cyclin D1 in embryonic germ cells promotes testicular teratoma initiation
    Denise Grant Lanza, Emily Packard Dawson, Priya Rao, Jason D. Heaney · 2016 · Cell Cycle
95. Isogambogenic Acid Inhibits the Growth of Glioma Through Activation of the AMPK-mTOR Pathway
    Wenyang Zhao, Fei Peng, Mengting Shu, Huailei Liu, Xu Hou, Xiaoxiong Wang, Junyi Ye, Boxian Zhao, Kaikai Wang, Zhong Chen et al. · 2017 · Cellular Physiology and Biochemistry
96. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia
    Janisha Patel, Xueliang Gao, Haizhen Wang · 2023 · International Journal of Molecular Sciences
97. BHLHE41 promotes U87 and U251 cell proliferation via ERK/cyclinD1 signaling pathway
    Chen Wang, Na Zhao, Qin Zheng, Di Zhang, Yang Liu · 2019 · Cancer Management and Research
98. DDA 1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle
    Lin Cheng, Qianmei Yang, Can Li, Lei Dai, Yang Yang, Qingnan Wang, Yu Ding, Junfeng Zhang, Lei Liu, Shuang Zhang et al. · 2017 · Journal of Cellular and Molecular Medicine
99. Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex
    Gerarduzzi, Casimiro, de Polo, Anna, Liu, Xue-Song, El Kharbili, Manale, Little, John B., Yuan, Zhi-Min · 2016 · Journal of Biological Chemistry
100. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
     Rosa Isela Gallagher, Julia Dianne Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina S. F. Yau, Nicholas O’Grady, Amrita B Basu, Ruixiao Lu, Michael J. Campbell, Mark Jesus M. Magbanua et al. · 2023 · Cell Reports Medicine